Skip to NavigationSkip to content


Novartis' Cosentyx gets European go-ahead in paediatric plaque psoriasis

Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients between the ages of six and 18 with moderate-to-severe plaque psoriasis.

UCB's investigational IL-17A and IL-17F inhibitor outclasses Novartis' Cosentyx in plaque psoriasis

UCB has revealed promising new data from a head-to-head trial pitting the company’s IL-17A and IL-17F inhibitor bimekizumab against Novartis’ IL-17A inhibitor Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis.

Bimekizumab was shown to outclass Cosentyx in achieving skin clearance after 16 weeks of treatment, represented by an improvement of 100% on the Psoriasis Area and Severity Index (PASI 100), hitting the study’s primary endpoint.

Novartis' Cosentyx hits primary goal in Phase 3 non-radiographic axial spondyloarthritis study

New Phase 3 data has been released on the efficacy of Novartis’ interleukin (IL)-17A inhibitor Cosentyx (secukinumab), showing that the therapy led to “significant and sustained improvements in signs and symptoms” of non-radiographic axial spondyloarthritis (nr-axSpA).

The debilitating condition is recorded as affecting around 1.7 million people across the largest five EU nations and the US, though, as a frequently undiagnosed condition, its true prevalence is likely much higher. Cosentyx secured approval in Europe for this indication in April this year.

EU approval for Novartis' Cosentyx in active non-radiographic axial spondyloarthritis

Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients.

The authorisation was awarded after Phase 3 data drawn from the largest-ever study of a biologic drug in nr-axSpA showed that Cosentyx met its primary endpoint in trials investigating its efficacy in treating the condition.

An estimated 1.7 million patients live with nr-axSpA across the US and the top five EU countries.

AbbVie's Skyrizi outpaces Novartis' Cosentyx in plaque psoriasis skin clearance

AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque psoriasis, hitting both its primary and all ranked secondary endpoints.

The data revealed “significantly higher” skin clearance rates for Skyrizi compared to Cosentyx, with 87% experiencing an improvement of at least 90% from baseline at 52 weeks of treatment, according to the Psoriasis Area and Severity Index (PASI), compared to just 57% with the latter.

Despite some advantages, Novartis' Cosentyx fails to outclass Humira in active psoriatic arthritis

Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – currently the world’s best-selling drug – in the treatment of active psoriatic arthritis (PsA).

While details on the findings of the study were scant, Novartis confirmed that its drug exhibited “numerically higher results” compared to AbbVie’s therapy with “statistically significant advantages” recorded in a pre-specified sensitivity analysis.

Novartis' Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs and symptoms of psoriatic arthritis in patients with and without enthesitis, a sub-group representing around 30-50% of the total incidence of the disease.

Pooled two-year data from a pair of Phase 3 studies indicated that patients taking Cosentyx achieved complete resolution of enthesitis at a faster rate than those receiving placebo, while improvement in signs and symptoms of the condition, measured on the American College of Rheumatology 50

Novartis' Cosentyx has strong Phase 3 interim showing in axial spondyloarthritis

Novartis has highlighted new data from its ongoing Phase 3 trial into the efficacy and safety of itsinterleukin-17A inhibitor Cosentyx (secukinumab) in the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), showing that the drug met its primary endpoint and all secondary endpoints.

Novartis provides promising update on Cosentyx in plaque psoriasis

Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that the therapy “improves inflammation and rapidly supresses IL-23” in cases of the disease.

Published in the Journal of Allergy and Clinical Immunology, the findings indicated that  Cosentyx generated a “substantial improvement” in inflammation for the majority of patients after as little as 12 weeks by modulating gene expression and reversing plaque histopathology.

Novartis' Cosentyx approved in China for plaque psoriasis

Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy, following review by the country’s National Medical Products Association (NMPA).

The approval was supported by a range of robust data, including from five-year Phase 3 extension studies in psoriasis, psoriatic arthritis and ankylosing spondylitis.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches